{"id":"autologous-transplantation-using-rituxan-beam","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Organ toxicity (cardiac, renal, hepatic)"}]},"_chembl":{"chemblId":"CHEMBL5315092","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab is a monoclonal antibody targeting CD20 on B cells, causing their depletion. The BEAM chemotherapy regimen (carmustine, etoposide, cytarabine, melphalan) provides myeloablative conditioning. Autologous hematopoietic stem cell transplantation then restores bone marrow function with patient's own stem cells, effectively resetting the immune system to eliminate autoreactive B cells.","oneSentence":"Rituximab depletes B cells, followed by high-dose chemotherapy (BEAM regimen) and autologous stem cell transplantation to reset the immune system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:01.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe autoimmune diseases (e.g., systemic sclerosis, multiple sclerosis, systemic lupus erythematosus)"}]},"trialDetails":[{"nctId":"NCT00329030","phase":"PHASE3","title":"Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-12","conditions":"Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Non-Hodgkin","enrollment":224},{"nctId":"NCT00345865","phase":"PHASE2","title":"Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08-24","conditions":"Lymphoma","enrollment":473},{"nctId":"NCT00992446","phase":"PHASE2","title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-09-02","conditions":"Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT00472056","phase":"PHASE2","title":"Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-03","conditions":"Lymphoma","enrollment":93}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rituximab"],"phase":"phase_3","status":"active","brandName":"Autologous transplantation using rituxan/BEAM","genericName":"Autologous transplantation using rituxan/BEAM","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab depletes B cells, followed by high-dose chemotherapy (BEAM regimen) and autologous stem cell transplantation to reset the immune system. Used for Severe autoimmune diseases (e.g., systemic sclerosis, multiple sclerosis, systemic lupus erythematosus).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}